CD8A and neoplasm: Subsequent research demonstrated that gemcitabine (Gem) could significantly restore the cross‐presentation capacity of tumor‐infiltrating DCs [233], reversing their semi‐mature state and enhancing tumor‐specific CD8+ T cell activation.